This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab.
All patients will have had Vigil™ prepared and stored from initial primary surgical
debulking. Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7
cells/intradermal injection once every 4 weeks and bevacizumab 10 mg/kg intravenously every 2
weeks.